Lyka Labs Peer Comparison

Lyka Labs Ltd. exhibits strong revenue growth but struggles with profitability and high valuation metrics compared to its peers. Companies like Cipla and Dr. Reddy's Laboratories lead in profitability while maintaining lower valuations. Overall, Lyka Labs presents a mixed outlook, positioned for growth yet facing challenges in profitability and high valuation ratios.

• • Lyka Labs shows a solid revenue growth rate of 19.47% YoY but has negative profitability metrics (ROE -6.02%).
• • Cipla and Dr. Reddy's Laboratories are notable for their strong profitability and more attractive valuations.
• • Divi's Laboratories has the highest PE ratio, indicating potential overvaluation despite decent growth.

• • Cipla Ltd.: Strong profitability metrics with a ROE of 16.63% and a low PE ratio of 23.73.
• • Dr. Reddy's Laboratories Ltd.: Excellent profitability with ROE of 21.76% and low PE of 15.50, making it highly attractive.
• • Mankind Pharma Ltd.: High growth with 18.12% revenue increase YoY and solid profitability.